You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Colorcon
Medtronic
Express Scripts
AstraZeneca
Dow
Merck

Last Updated: December 3, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Evogliptin

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Evogliptin?

Evogliptin is an investigational drug.

There have been 19 clinical trials for Evogliptin. The most recent clinical trial was a Phase 3 trial, which was initiated on June 1st 2016.

The most common disease conditions in clinical trials are Diabetes Mellitus, Type 2, Diabetes Mellitus, and Liver Diseases. The leading clinical trial sponsors are Dong-A ST Co., Ltd., Asan Medical Center, and REDNVIA.

There are five US patents protecting this investigational drug and ninety-seven international patents.

Recent Clinical Trials for Evogliptin
TitleSponsorPhase
Clinical Trials to Compare the Effects of Pioglitazone and Evogliptin on Hepatic Fibrosis in Patients With Chronic Hepatitis B With Significant Hepatic Fibrosis With Type 2 DiabetesYonsei UniversityPhase 4
Randomized, Open-label Trial of Inhibitory Effect of Evogliptin on Progression of CAVDREDNVIAPhase 4
Randomized, Open-label Trial of Inhibitory Effect of Evogliptin on Progression of CAVDAsan Medical CenterPhase 4

See all Evogliptin clinical trials

Clinical Trial Summary for Evogliptin

Top disease conditions for Evogliptin
Top clinical trial sponsors for Evogliptin

See all Evogliptin clinical trials

US Patents for Evogliptin

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Evogliptin   Start Trial Composition containing a DPP-IV inhibitor for preventing or treating renal diseases DONG-A ST Co., Ltd (Seoul, KR)   Start Trial
Evogliptin   Start Trial DPP-IV inhibitor including beta-amino group, preparation method thereof and pharmaceutical composition containing the same for preventing and treating diabetes or obesity Dong-A Pharm. Co., Ltd. (Seoul, KR)   Start Trial
Evogliptin   Start Trial Pharmaceutical composition for prevention and treatment of diabetes or obesity comprising a compound that inhibits activity of dipeptidyl peptidase-IV, and other antidiabetic or antiobesity agents as active ingredients Dong-A Pharmaceutical Co. Ltd. (Seoul, KR)   Start Trial
Evogliptin   Start Trial Method for manufacturing dipeptidyl peptidase-IV inhibitor and intermediate Dong-A Pharmaceutical. Co., Ltd (Seoul, KR)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Evogliptin

Drugname Country Document Number Estimated Expiration Related US Patent
Evogliptin Australia AU2014299575 2033-06-26   Start Trial
Evogliptin Brazil BR112015032410 2033-06-26   Start Trial
Evogliptin Canada CA2916698 2033-06-26   Start Trial
Evogliptin China CN105555275 2033-06-26   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Medtronic
Express Scripts
AstraZeneca
Dow
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.